Determinants of Survival with Combined HER2 and PD-1 Blockade in Metastatic Esophagogastric Cancer

PURPOSE: We report updated clinical outcomes from a phase II study of pembrolizumab, trastuzumab, and chemotherapy (PTC) in metastatic esophagogastric cancer in conjunction with outcomes from an independent Memorial Sloan Kettering (MSK) cohort. PATIENTS AND METHODS: The significance of pretreatment...

Descripción completa

Detalles Bibliográficos
Autores principales: Maron, Steven B., Chatila, Walid, Walch, Henry, Chou, Joanne F., Ceglia, Nicholas, Ptashkin, Ryan, Do, Richard Kinh Gian, Paroder, Viktoriya, Pandit-Taskar, Neeta, Lewis, Jason S., Biachi De Castria, Tiago, Sabwa, Shalom, Socolow, Fiona, Feder, Lara, Thomas, Jasmine, Schulze, Isabell, Kim, Kwanghee, Elzein, Arijh, Bojilova, Viktoria, Zatzman, Matthew, Bhanot, Umesh, Nagy, Rebecca J., Lee, Jeeyun, Simmons, Marc, Segal, Michal, Ku, Geoffrey Yuyat, Ilson, David H., Capanu, Marinela, Hechtman, Jaclyn F., Merghoub, Taha, Shah, Sohrab, Schultz, Nikolaus, Solit, David B., Janjigian, Yelena Y.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2023
Materias:
Clinical Trials: Targeted Therapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10502449/
https://www.ncbi.nlm.nih.gov/pubmed/37406106
http://dx.doi.org/10.1158/1078-0432.CCR-22-3769

Ejemplares similares

Ejemplares similares